首页> 美国卫生研究院文献>PLoS Clinical Trials >Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
【2h】

Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors

机译:双环杂芳族哒嗪酮和吡唑酮衍生物作为磷酸二酯酶3A(PDE3A)抑制剂的对接和定量构效关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in platelets involved in the cAMP regulation pathway of platelet aggregation. PDE3A inhibitors have been designed as potential antiplatelet agents. In this work, a homology model of PDE3A was developed and used to obtain the binding modes of bicyclic heteroaromatic pyridazinones and pyrazolones. Most of the studied compounds adopted similar orientations within the PDE3A active site, establishing hydrogen bonds with catalytic amino acids. Besides, the structure-activity relationship of the studied inhibitors was described by using a field-based 3D-QSAR method. Different structure alignment strategies were employed, including template-based and docking-based alignments. Adequate correlation models were obtained according to internal and external validations. In general, QSAR models revealed that steric and hydrophobic fields describe the different inhibitory activities of the compounds, where the hydrogen bond donor and acceptor fields have minor contributions. It should be stressed that structural elements of PDE3A inhibitors are reported here, through descriptions of their binding interactions and their differential affinities. In this sense, the present results could be useful in the future design of more specific and potent PDE3A inhibitors that may be used for the treatment of cardiovascular diseases.
机译:PDE3属于磷酸二酯酶家族,其中PDE3A亚型是参与血小板聚集的cAMP调节途径的血小板中的主要亚型。 PDE3A抑制剂已被设计为潜在的抗血小板药。在这项工作中,开发了PDE3A的同源性模型,并用于获得双环杂芳族哒嗪酮和吡唑啉酮的结合模式。大多数研究的化合物在PDE3A活性位点内采用相似的方向,与催化氨基酸建立氢键。此外,通过基于现场的3D-QSAR方法描述了所研究抑制剂的构效关系。采用了不同的结构比对策略,包括基于模板的比对和基于对接的比对。根据内部和外部验证,获得了足够的相关性模型。通常,QSAR模型显示,空间和疏水场描述了化合物的不同抑制活性,其中氢键供体和受体场贡献较小。应该强调的是,这里通过对PDE3A抑制剂的结合相互作用及其不同亲和力的描述,报道了其结构元素。从这个意义上讲,目前的结果可能在将来设计可用于治疗心血管疾病的更特异性和更有效的PDE3A抑制剂中有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号